Cowealth Medical Holding Co Ltd

Cowealth Medical's capital structure shows a debt-to-equity ratio of 0.33, indicating a relatively conservative leverage position compared to industry norms. The company's liquidity is assessed as medium, with a current ratio of 3.67, suggesting it can cover short-term obligations but with limited excess capacity. Free cash flow of TWD 22.84 million provides some flexibility, though operating cash flow is negative at TWD -372.5 million, signaling potential working capital or operational inefficiencies.

Profitability metrics reveal a weak return profile. Return on equity (ROE) of 0.19% and return on assets (ROA) of 0.08% are significantly below the industry median for Advanced Medical Equipment & Technology, which typically exceeds 5% ROE and 2% ROA. Gross profit of TWD 228.4 million on TWD 1.05 billion in revenue yields a 21.8% margin, but operating income of TWD 35.4 million translates to a 3.4% margin, indicating high operating costs or pricing pressures.

Geographic and segment exposure is not explicitly disclosed in the available data, but the company's revenue concentration appears to be primarily in its core medical equipment and technology business. No material diversification across product lines or regions is evident from the financial snapshot, which may increase vulnerability to sector-specific shocks.

Growth trajectory is constrained by weak profitability and negative operating cash flow. Revenue of TWD 1.05 billion in the latest period shows no year-over-year growth data, and the outlook for the current and next fiscal years is not provided. The company's capital expenditure of TWD -12.48 million suggests minimal investment in expansion or innovation, which could limit long-term growth potential.

Risk factors include liquidity concerns due to negative net cash after subtracting total debt, as well as low dilution risk with shares outstanding unchanged between basic and diluted measures. No recent equity issuance or ATM/shelf registration is disclosed, and the company's dilution potential is assessed as low. However, the negative operating cash flow and low returns suggest operational inefficiencies that could pressure liquidity in the near term.

Recent events or filings are not detailed in the available data, but the financial snapshot indicates a need for operational improvement. The company's free cash flow is insufficient to cover debt servicing or meaningful reinvestment, and the absence of positive operating cash flow raises questions about its ability to sustain operations without external financing.

Return on equity of 0.19% beats the cohort median of -4.7%, showing positive capital efficiency despite low absolute returns.

Capex to revenue ratio of -1.2% ranks in the top quartile, suggesting minimal capital intensity requirements.

Dilution risk is assessed as low, providing some protection to existing shareholders against equity value erosion.

Debt-to-equity ratio of 0.33 is well below the cohort median of 0.06, implying higher leverage risk.

Cash conversion of -71.03% sits in the bottom quartile, highlighting poor ability to turn earnings into cash.

Revenue TWD 5.63B, +9,5% YoY; Operating income +9,2% YoY.

• ▍Revenue TWD 5.63B, +9,5% YoY
• ▍Operating income +9,2% YoY
• ▍Net income −32,5% YoY
• ▍Free cash flow −4,0% YoY
• ▍Net margin 1.7%